Cargando…

Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling

Background and Aims: Pulmonary Hypertension (PH) represents an aetiologically and clinically heterogeneous disorder accompanied by a severely impaired prognosis. Key steps of PH pathogenesis are vascular and right ventricular myocardial remodelling entailing the re-occurrence of fetal variants of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bäz, Laura, Roßberg, Michelle, Grün, Katja, Kretzschmar, Daniel, Berndt, Alexander, Schulze, P. Christian, Jung, Christian, Franz, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229629/
https://www.ncbi.nlm.nih.gov/pubmed/34207881
http://dx.doi.org/10.3390/jcm10122559
_version_ 1783713022972264448
author Bäz, Laura
Roßberg, Michelle
Grün, Katja
Kretzschmar, Daniel
Berndt, Alexander
Schulze, P. Christian
Jung, Christian
Franz, Marcus
author_facet Bäz, Laura
Roßberg, Michelle
Grün, Katja
Kretzschmar, Daniel
Berndt, Alexander
Schulze, P. Christian
Jung, Christian
Franz, Marcus
author_sort Bäz, Laura
collection PubMed
description Background and Aims: Pulmonary Hypertension (PH) represents an aetiologically and clinically heterogeneous disorder accompanied by a severely impaired prognosis. Key steps of PH pathogenesis are vascular and right ventricular myocardial remodelling entailing the re-occurrence of fetal variants of the cell adhesion modulating protein fibronectin (Fn) being virtually absent in healthy adult tissues. These variants are liberated into circulation and are therefore qualified as excellent novel serum biomarkers. Moreover, these molecules might serve as promising therapeutic targets. The current study was aimed at quantifying the serum levels of two functionally important fetal Fn variants (ED-A(+) and ED-B(+) Fn) in patients suffering from PH due to different aetiologies compared to healthy controls. Methods: Serum levels of ED-A(+) and ED-B(+) Fn were quantified using novel ELISA protocols established and validated in our group in 80 PH patients and 40 controls. Results were analysed with respect to clinical, laboratory, echocardiographic and functional parameters. Results: Serum levels of ED-A(+) Fn (p = 0.001) but not ED-B(+) Fn (p = 0.722) were significantly increased in PH patients compared to healthy controls. Thus, the following analyses were performed only for ED-A(+) Fn. When dividing PH patients into different aetiological groups according to current ESC guidelines, the increase in ED-A(+) Fn in PH patients compared to controls remained significant for group 1 (p = 0.032), 2 (p = 0.007) and 3 (p = 0.001) but not for group 4 (p = 0.156). Correlation analysis revealed a significant relation between ED-A(+) Fn and brain natriuretic peptide (BNP) (r = 0.310; p = 0.002), six minutes’ walk test (r = −0.275; p = 0.02) and systolic pulmonary artery pressure (PAPsys) (r = 0.364; p < 0.001). By logistic regression analysis (backward elimination WALD) including a variety of potentially relevant patients’ characteristics, only chronic kidney disease (CKD) (OR: 8.866; CI: 1.779–44.187; p = 0.008), C reactive protein (CRP) (OR: 1.194; CI: 1.011–1.410; p = 0.037) and ED-A(+) Fn (OR: 1.045; CI: 1.011–1.080; p = 0.009) could be identified as independent predictors of the presence of PH. Conclusions: Against the background of our results, ED-A(+) Fn could serve as a promising novel biomarker of PH with potential value for initial diagnosis and aetiological differentiation. Moreover, it might contribute to more precise risk stratification of PH patients. Beyond that, the future role of ED-A(+) Fn as a therapeutic target has to be evaluated in further studies.
format Online
Article
Text
id pubmed-8229629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82296292021-06-26 Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling Bäz, Laura Roßberg, Michelle Grün, Katja Kretzschmar, Daniel Berndt, Alexander Schulze, P. Christian Jung, Christian Franz, Marcus J Clin Med Article Background and Aims: Pulmonary Hypertension (PH) represents an aetiologically and clinically heterogeneous disorder accompanied by a severely impaired prognosis. Key steps of PH pathogenesis are vascular and right ventricular myocardial remodelling entailing the re-occurrence of fetal variants of the cell adhesion modulating protein fibronectin (Fn) being virtually absent in healthy adult tissues. These variants are liberated into circulation and are therefore qualified as excellent novel serum biomarkers. Moreover, these molecules might serve as promising therapeutic targets. The current study was aimed at quantifying the serum levels of two functionally important fetal Fn variants (ED-A(+) and ED-B(+) Fn) in patients suffering from PH due to different aetiologies compared to healthy controls. Methods: Serum levels of ED-A(+) and ED-B(+) Fn were quantified using novel ELISA protocols established and validated in our group in 80 PH patients and 40 controls. Results were analysed with respect to clinical, laboratory, echocardiographic and functional parameters. Results: Serum levels of ED-A(+) Fn (p = 0.001) but not ED-B(+) Fn (p = 0.722) were significantly increased in PH patients compared to healthy controls. Thus, the following analyses were performed only for ED-A(+) Fn. When dividing PH patients into different aetiological groups according to current ESC guidelines, the increase in ED-A(+) Fn in PH patients compared to controls remained significant for group 1 (p = 0.032), 2 (p = 0.007) and 3 (p = 0.001) but not for group 4 (p = 0.156). Correlation analysis revealed a significant relation between ED-A(+) Fn and brain natriuretic peptide (BNP) (r = 0.310; p = 0.002), six minutes’ walk test (r = −0.275; p = 0.02) and systolic pulmonary artery pressure (PAPsys) (r = 0.364; p < 0.001). By logistic regression analysis (backward elimination WALD) including a variety of potentially relevant patients’ characteristics, only chronic kidney disease (CKD) (OR: 8.866; CI: 1.779–44.187; p = 0.008), C reactive protein (CRP) (OR: 1.194; CI: 1.011–1.410; p = 0.037) and ED-A(+) Fn (OR: 1.045; CI: 1.011–1.080; p = 0.009) could be identified as independent predictors of the presence of PH. Conclusions: Against the background of our results, ED-A(+) Fn could serve as a promising novel biomarker of PH with potential value for initial diagnosis and aetiological differentiation. Moreover, it might contribute to more precise risk stratification of PH patients. Beyond that, the future role of ED-A(+) Fn as a therapeutic target has to be evaluated in further studies. MDPI 2021-06-09 /pmc/articles/PMC8229629/ /pubmed/34207881 http://dx.doi.org/10.3390/jcm10122559 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bäz, Laura
Roßberg, Michelle
Grün, Katja
Kretzschmar, Daniel
Berndt, Alexander
Schulze, P. Christian
Jung, Christian
Franz, Marcus
Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title_full Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title_fullStr Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title_full_unstemmed Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title_short Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A(+) Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling
title_sort serum liberation of fetal fibronectin variants in patients with pulmonary hypertension: ed-a(+) fn as promising novel biomarker of pulmonary vascular and right ventricular myocardial remodeling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229629/
https://www.ncbi.nlm.nih.gov/pubmed/34207881
http://dx.doi.org/10.3390/jcm10122559
work_keys_str_mv AT bazlaura serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT roßbergmichelle serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT grunkatja serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT kretzschmardaniel serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT berndtalexander serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT schulzepchristian serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT jungchristian serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling
AT franzmarcus serumliberationoffetalfibronectinvariantsinpatientswithpulmonaryhypertensionedafnaspromisingnovelbiomarkerofpulmonaryvascularandrightventricularmyocardialremodeling